AXL expression is associated with increased risk of metastasis and poor survival in a variety of solid cancers, including breast cancer, non‐small‐cell lung adenocarcinoma, ovarian cancer, clear cell renal carcinoma, and pancreatic cancer [28, 29, 30, 31, 32]. Here, AXL is linked to ovarian cancer.